Market Access · Swiss Launch
From Approval to Patient Access in Switzerland
Connecting evidence, pricing, reimbursement and stakeholder engagement
Regulatory approval opens the door. Market access determines whether patients can walk through it.
Discuss your Swiss access strategy
Preparing your Swiss market-access strategy?
Tell us briefly where you stand. We will get back to you personally.
Thank you. We have received your request.
[Philipp Ansorge or a member of the team will get back to you within X working days.]
Approval opens the door. Access decides whether patients can use it.
In Switzerland, a successful access pathway requires early coordination between evidence, pricing, reimbursement and stakeholder expectations. Companies that address these questions only after regulatory milestones have been reached may face avoidable delays or difficult trade-offs.
At Luminance Health, we support companies in developing practical market-access roadmaps, preparing value and reimbursement dossiers, engaging with relevant stakeholders and navigating pricing and reimbursement discussions. The goal is to connect product strategy with the realities of the Swiss healthcare system and support access for the patients who need innovative therapies.
Evidence
Evidence requirements are clarified before they become critical dependencies.
Pricing
Pricing implications are understood early, not discovered late.
Reimbursement
Reimbursement scenarios are worked out before decisions are locked in.
Stakeholders
Expectations of the relevant stakeholders are known and addressed.
Plan access before it becomes a bottleneck
Addressing access after regulatory milestones
Companies that take this route may face:
- Avoidable delays
- Difficult trade-offs
- Critical dependencies that surface too late
Planning access early
Early planning can help you clarify:
- Evidence requirements
- Reimbursement scenarios
- Pricing implications
- Potential access pathways
From your challenge to a practical solution
We connect your product strategy with the realities of the Swiss healthcare system, so that innovative therapies can reach the patients who need them.
Market-access roadmaps
Your challenge
You need clarity on the access pathway and what it requires from your company.
What we do
We develop practical roadmaps, so that key questions are answered before they become critical dependencies.
- Evidence requirements
- Reimbursement scenarios
- Pricing implications
- Potential access pathways
Value and reimbursement dossiers
Your challenge
Your value story must hold up in the Swiss reimbursement context.
What we do
We prepare dossiers that connect your product strategy with the realities of the Swiss healthcare system.
- Value dossier preparation
- Reimbursement dossier preparation
- Link to your product strategy
- Swiss healthcare context
Stakeholder engagement
Your challenge
You need to reach the right stakeholders and understand their expectations.
What we do
We engage with the relevant stakeholders, so that expectations are known and addressed early.
- Stakeholder identification
- Expectation management
- Early engagement
- Alignment with evidence and pricing
Pricing and reimbursement discussions
Your challenge
Your pricing and reimbursement discussions are coming up.
What we do
We support you through the discussions, from preparation to dialogue with the relevant parties.
- Discussion preparation
- Pricing implications
- Reimbursement scenarios
- Dialogue with relevant parties
Are you preparing your Swiss pricing, reimbursement or market-access strategy?
Let's discuss.
Get in touch
Your contact
Philipp Ansorge
Function Head Market Access, Luminance Health
Regulatory approval opens the door. Market access determines whether patients can walk through it.
As Market Access Lead, Philipp helps companies turn clinical and scientific value into clear market access strategies for commercial success. He develops practical, evidence-based approaches for pricing, reimbursement and stakeholder engagement. With strong expertise in European and Swiss regulations, he supports clients in building convincing value propositions, securing reimbursement and maximizing product potential throughout the product lifecycle.
Philipp is also the Pharmacovigilance Responsible Person at Luminance Health and provides cross-functional strategic advice across Quality Assurance, Pharmacovigilance and Market Access. Over the course of his career, he has held numerous key mandates, including Swiss Responsible Person, Pharmacovigilance Responsible Person, EudraVigilance Responsible Person and EU-QPPV.
He completed postdoctoral research in ocular drug delivery at the University of Zurich and University Hospital Zurich and holds a PhD in Biochemistry from the University of Zurich, along with degrees in Life Science and Chemistry.
p.ansorge@luminance-health.comFrequently asked questions
When should we start planning market access?
Early. Companies that address pricing, reimbursement and evidence questions only after regulatory milestones may face avoidable delays or difficult trade-offs. Early planning helps you clarify requirements, scenarios and pathways before they become critical dependencies.
What can Luminance Health do for us?
We develop practical market-access roadmaps, prepare value and reimbursement dossiers, engage with relevant stakeholders and support you in pricing and reimbursement discussions.
Who will I speak with?
Your first conversation is with Philipp Ansorge, Function Head Market Access, or a member of his team. [Confirm]
Is the first conversation binding?
[Confirm: The initial conversation is free and non-binding.]
What happens to my data?
We use your details to respond to your enquiry. You can find more in our privacy policy.
Contact
Let's discuss your Swiss market-access strategy
Tell us where you stand. We will tell you honestly how we can help.
What happens next
Contact us
We read every request personally.
Thank you. We have received your request.
[Philipp Ansorge or a member of the team will get back to you within X working days.]